OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN

被引：0
|
作者：
Melody, Megan [1 ]
Przybylski, Daniel [1 ]
Robinson, Adam [1 ]
Lin, Adam [1 ]
Gordon, Leo [1 ]
Adekola, Kehinde [1 ]
Singhal, Seema [1 ]
Mehta, Jayesh [1 ]
Moreira, Jonathan [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P086
引用
收藏
页码：210 / 211
页数：2
相关论文
共 50 条
  • [1] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Madduri, Deepu
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Lin, Yi
    Siegel, David
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Cavo, Michele
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Rambaldi, Alessandro
    Reece, Donna
    Petrocca, Fabio
    Massaro, Monica
    Connarn, Jamie N.
    Kaiser, Shari
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08): : 705 - 716
  • [2] Belantamab mafodotin for relapsed or refractory multiple myeloma
    David Gil-Sierra, Manuel
    del Pilar Briceno-Casado, Maria
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (06) : 1375 - 1380
  • [3] Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
    Little, Jessica S.
    Shah, Parth
    Sperling, Adam S.
    Branagan, Andrew R.
    Nadeem, Omar
    Yee, Andrew J.
    Raje, Noopur S.
    Munshi, Nikhil C.
    Hammond, Sarah
    [J]. BLOOD, 2021, 138 : 3839 - +
  • [4] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
    Sheikh, Semira
    Lebel, Eyal
    Trudel, Suzanne
    [J]. FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
  • [5] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
    Condorelli, Annalisa
    Garibaldi, Bruno
    Gagliano, Caterina
    Romano, Alessandra
    Del Fabro, Vittorio
    Parrinello, Nunziatina Laura
    Longo, Antonio
    Cosentino, Sebastiano
    Di Raimondo, Francesco
    Conticello, Concetta
    [J]. ACTA HAEMATOLOGICA, 2024, 147 (04) : 493 - 498
  • [6] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
    Stocker, Nicolas
    [J]. HEMATOLOGIE, 2020, 26 (02): : 99 - 100
  • [7] The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
    Becnel, Melody R.
    Lee, Hans C.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [8] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
    Condorelli, Annalisa
    Garibaldi, Bruno
    Gagliano, Caterina
    Romano, Alessandra
    Del Fabro, Vittorio
    Parrinello, Nunziatina Laura
    Longo, Antonio
    Cosentino, Sebastiano
    Di Raimondo, Francesco
    Conticello, Concetta
    [J]. ACTA HAEMATOLOGICA, 2021,
  • [9] FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
    Sharma, Poornima
    Kanapuru, Bindu
    George, Bindu
    Lin, Xue
    Xu, Zhenzhen
    Bryan, Wilson W.
    Pazdur, Richard
    Theoret, Marc R.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (09) : 1759 - 1764
  • [10] Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances
    Tu, Wei
    Xiao, Yajuan
    Wang, Yadong
    Luo, Rongcheng
    Chen, Zhe-Sheng
    [J]. DRUGS OF TODAY, 2022, 58 (03) : 117 - 132
12345